Alnylam Pharmaceuticals (ALNY) Intangibles (2009 - 2012)
Alnylam Pharmaceuticals (ALNY) posted Intangibles of $145000.0 for Q3 2012, down 22.87% on a QoQ basis from $188000.0 in Q2 2012, and down 54.4% year-over-year from $318000.0 in Q4 2011.
Alnylam Pharmaceuticals (ALNY) Intangibles (2009 - 2012) Analysis & Trends
Alnylam Pharmaceuticals' Intangibles history runs 4 years deep, the most recent figure standing at $145000.0 for Q3 2012.
- Quarterly Intangibles fell 54.4% year-over-year to $145000.0 in Q3 2012, while the trailing twelve-month figure through Sep 2012 was $145000.0 (down 54.4% YoY) and the FY2011 annual result came in at $275000.0, down 38.62% from the prior year.
- Intangibles was $145000.0 for Q3 2012 at Alnylam Pharmaceuticals, down from $188000.0 in the prior quarter.
- Across five years, Intangibles topped out at $622000.0 in Q4 2009 and bottomed at $145000.0 in Q3 2012.
- A 4-year average of $365363.6 and a median of $361000.0 in 2011 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2010 — Intangibles declined 27.97% — and 2012, when it tumbled 54.4%.
- Alnylam Pharmaceuticals' Intangibles stood at $622000.0 in 2009, then retreated by 27.97% to $448000.0 in 2010, then tumbled by 38.62% to $275000.0 in 2011, then plunged by 47.27% to $145000.0 in 2012.
- Business Quant data shows ALNY's Intangibles at $145000.0 in Q3 2012, $188000.0 in Q2 2012, and $231000.0 in Q1 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 16.97 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 11,640.44 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 61.68 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 418.50 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.29 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 55.80 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | 145,000.00 |
| Jun 30, 2012 | 188,000.00 |
| Mar 31, 2012 | 231,000.00 |
| Dec 31, 2011 | 275,000.00 |
| Sep 30, 2011 | 318,000.00 |
| Jun 30, 2011 | 361,000.00 |
| Mar 31, 2011 | 405,000.00 |
| Dec 31, 2010 | 448,000.00 |
| Sep 30, 2010 | 491,000.00 |
| Jun 30, 2010 | 535,000.00 |
| Dec 31, 2009 | 622,000.00 |